[Use of Varitect in the prevention of diseases in children caused by varicella-zoster viruses].
The authors report on prophylaxis experience with specific human varicella-zoster immunoglobulin for intravenous use Varitect (produced by Biotest) in two children within incubation period of varicella. One patient was a newborn child whose mother had acquired varicella three days before the delivery and Varitect was administered immediately there after. The other patient had acute lymphoblastic leukemia; it was administered Varitect on the fifth day of incubation period. In the first patient the disease did not appear at all, in the second patient the course of disease had been mitigated and without complications within the extended incubation period.
Bartosová
D
D
Klinika dĕtských infekcních nemocí FDN JGM, Brno.
Wiedermannová
D
D
D002644:Chickenpox / Q000517:prevention & control*; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007106:Immune Sera / Q000008:administration & dosage*; D007116:Immunization, Passive; D016867:Immunocompromised Host; D007231:Infant, Newborn
D007106:Immune Sera; C030799:varicella-zoster immune globulin